Vascular Strategies
is dedicated to the discovery and expansion of treatment options for Cardiovascular Disease. Our company is a complete resource for functional testing and development of therapeutic candidates for arresting and reversing atherosclerosis through modulation of HDL , Reverse Cholesterol Transport (RCT), and Immune Mediators .

The incidence of atherosclerosis and accompanying coronary disease remain significant issues, both medically and financially. An estimated 180 million individuals are affected at various stages of the disease worldwide, with "clinical" cases diagnosed in more than 34 million patients.  Nearly 2600 Americans die of cardiovascular disease every day accounting for 38.5% of all deaths. Despite the success and popularity of statin therapy, the rate of CVD remains exceedingly high and is increasing in all groups, especially in women.  Financially, the cost of cardiovascular disease care in the US in 2006 was more than $380 billion (NHLBI), and it is expected to increase as life expectancy increases.

Importantly, HDL and RCTare critical factors to the progression and regression of this disease process.